Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now.
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies.
Simulation-Guided Clinical Trials: Is EU Law Ready?
Simulations do not replace human judgment: they inform it, making transparent what would otherwise remain a “black box.” EU law does not require them today; but a proportionate embrace, in the right legislative vehicle, with clear methodological standards, and without crushing noncommercial research, could make trials safer, faster, cheaper, and more reliable, without sacrificing rigor.
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing group of companies developing therapies that reset the immune system to treat autoimmune disease.
What’s Driving the Consumerization of Healthcare?
Patients increasingly expect convenient, consumer-focused healthcare experiences, panelists said at the recent MedCity INVEST Digital Health Conference.